This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon a in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.
Cytogenetics of Chronic Myeloid Leukemia (CML).- The Biology and
Pathogenesis of Chronic Myeloid Leukaemia.- Epidemiology of Chronic Myeloid
Leukemia.-Imatinib and the first line CML Therapy.- CML Therapy: A Focus on
Second and Third Generation Tyrosine Kinase Inhibitors.- Adverse events
associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in
chronic myeloid leukemia.- Pharmacoeconomic considerations for tyrosine
kinase inhibitors in the treatment of chronic myeloid leukemia.-
Standardization of molecular monitoring for chronic myeloid leukemia: 2021
update.- Prognostic Scores for Patients with Chronic Myeloid Leukemia under
Particular Consideration of Disease-Specific Death.- A Review and an Update
of European LeukemiaNet Recommendations for the Management of Chronic Myeloid
Leukemia.- The Role of Hematopoietic Stem Cell Transplantation in CML.- CML
end-phase and blast crisis: implications and management.- The
Interferon-alpha Revival in CML.- Managing Pregnancy in Chronic Myeloid
Leukemia.- Response-Related Predictors of Survival and of Treatment Free
Remission in CML.- Discontinuation or cessation of tyrosine kinase inhibitor
treatment in Chronic myeloid leukemia patients with deep molecular response.
Rüdiger Hehlmann is a Professor of Medicine at the Mannheim Medical Faculty of the University of Heidelberg, Germany.
Founder and Chair, European LeukemiaNet (ELN)
Founder and chair of the German CML Study Group 1982-2017
Former Secretary General
International Association of Comparative Research on Leukemia & Related Diseases (IACRLRD)
Former Chief of Medicine, Dean & President
German Society of Hematology and Oncology
Honorary member of the Polish and German Societies for Hematology and Oncology
Current focus: promotion of cooperative research for curing leukemia
